Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like Cell Adhesion Molecules

Immunoglobulin-like cell adhesion molecules or Ig-CAMs are a versatile group of cell surface glycoproteins belonging to the immunoglobulin protein superfamily. Ig-CAMs possess the characteristic immunoglobulin protein domains and other domains such as the fibronectin type III domain. The Ig domains are glycosylated to varying degrees in different Ig-CAMs.
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...

Cells of the Adaptive Immune Response

Cells of the Adaptive Immune Response

The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...

Intracellular Signaling Affects Focal Adhesions

Intracellular Signaling Affects Focal Adhesions

Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Assessment of 2-aminothiazoline-4-carboxylic acid (ATCA) formation and identification of robust serum metabolic biomarkers for acute cyanide exposure in mice fed diets with varying methionine and cystine content.

Archives of toxicology·2026

Same author

Three Fatal Gestational Psittacosis Cases Caused by Chlamydia psittaci Strains Belonging to Closely Related Lineages, Japan.

Emerging infectious diseases·2026

Same author

CD69 regulates the tissue dynamics of epigenetically imprinted memory CD4<sup>+</sup> T cells.

Science advances·2026

Same author

Neoantigen Targeting as a Novel Approach for Therapy-Resistant Tumors.

Molecular diagnosis & therapy·2026

Same author

Preclinical efficacy of combination therapy with allogeneic induced pluripotent stem cell-derived invariant natural killer T and α-galactosylceramide-pulsed antigen-presenting cells.

Stem cell research & therapy·2026

Same author

LSD1 inhibitor, TAS1440, disrupts INSM1-LSD1 complex activating tumor-suppressive pathways via transcriptional reprogramming in neuroendocrine SCLC.

Nature communications·2026

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Adjuvant activity mediated by iNKT cells.

Shinichiro Fujii¹, Shinichiro Motohashi, Kanako Shimizu

¹Research Unit for Cellular Immunotherapy, RIKEN Research Center for Allergy and Immunology, 1-7-22, Suehiro-cho, Tsurumi-ku, Yokohama, Japan.

Seminars in Immunology

|November 27, 2009

Summary

Invariant natural killer T (iNKT) cells boost immunity by producing IFN-gamma. Targeted iNKT therapy in lung cancer patients showed prolonged survival, with 60% living over 2 years without progression.

More Related Videos

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

Related Experiment Videos

Last Updated: Jun 18, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation

Published on: September 16, 2018

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

In Vitro Cellular Activity Evaluation of the Nanoemulsion Vaccine Adjuvant Ophiopogonin D

Published on: December 9, 2022

Area of Science:

Immunology
Oncology

Background:

Invariant natural killer T (iNKT) cells possess potent adjuvant properties.
Their ability to secrete large quantities of Interferon-gamma (IFN-gamma) activates innate and adaptive immune cells, orchestrating protective immunity.

Purpose of the Study:

To develop and evaluate an iNKT cell-targeted adjuvant therapy.
To assess the safety and efficacy of this therapy in patients with advanced lung cancer.

Main Methods:

A phase I/IIa clinical trial was conducted.
Patients with advanced lung cancer received the novel iNKT cell-targeted adjuvant therapy.

Main Results:

A subset of patients exhibiting elevated levels of IFN-gamma-producing cells demonstrated significantly prolonged survival.
The median survival time for this group was 31.9 months.
Remarkably, 60% of patients in this subgroup survived beyond 2 years, remaining free from tumor progression and metastasis.

Conclusions:

iNKT cell-targeted adjuvant therapy shows promise in enhancing anti-tumor immunity.
The therapy may lead to improved survival outcomes in advanced lung cancer patients, particularly those with increased IFN-gamma production.